Andre Olivier, MD
Cardiovascular Disease · Lebanon, TNNPI 1558386771
Payments from drug & device makers
Across 624 payments — averaging $54.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$12K
- E.r. Squibb & Sons, L.L.C.$9K
- Boston Scientific$3K
- Medtronic$3K
- Actelion Pharmaceuticals US, Inc.$2K
- Boehringer Ingelheim$1K
- plus $5K from 26 others
What the payments were for
- Consulting fees$2,3007%
- Speaking & faculty fees$16,68549%
- Travel & lodging$1,0463%
- Food & beverage$13,96841%
- Education$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 26 | $11,641 |
| E.r. Squibb & Sons, L.L.C. | 66 | $8,621 |
| Boston Scientific | 84 | $2,716 |
| Medtronic | 37 | $2,683 |
| Actelion Pharmaceuticals US, Inc. | 120 | $2,441 |
| Boehringer Ingelheim | 62 | $1,050 |
| Johnson & Johnson | 60 | $883 |
| Amgen | 33 | $704 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 29 | $616 |
| Merck | 15 | $347 |
| Edwards Lifesciences | 7 | $277 |
| Novartis | 15 | $274 |
| AstraZeneca | 16 | $257 |
| Abbott | 3 | $256 |
| Amarin Pharma, Inc. | 11 | $179 |
| Biotronik Inc. | 6 | $171 |
| Irhythm Technologies, Inc. | 2 | $154 |
| Lexicon Pharmaceuticals, Inc. | 5 | $131 |
| Heartflow, Inc. | 1 | $124 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $62 |
| Sanofi-aventis U.S. LLC | 4 | $57 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $56 |
| Vital Connect, Inc | 2 | $49 |
| Novo Nordisk | 2 | $48 |
| Bayer | 3 | $44 |
| Scpharmaceuticals Inc. | 2 | $42 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Shockwave Medical, Inc | 1 | $29 |
| ZOLL Respicardia, Inc. | 1 | $26 |
| GSK | 1 | $25 |
| Baxter Healthcare | 1 | $13 |
| Philips North America LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$17,421
- Micra$1,957
- WATCHMAN FLX$790
- WATCHMAN Access System$615
- UPTRAVI$352
- OPSUMIT$352
- AURORA EV-ICD MRI SURESCAN$160
- Watchman$125
- Repatha$125
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$125
- FFRct$124
- ASSURITY$117
- WINREVAIR$117
- XARELTO$105
- LifeVest$103
How this compares
$34,021 in reported general payments places this provider in the 80th percentile of 429 cardiovascular disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,064 | $1,079,246 |
| EntrestoSacubitril/Valsartan | 147 | $177,212 |
| Repatha SureclickEvolocumab | 150 | $144,355 |
| XareltoRivaroxaban | 128 | $127,302 |
| JardianceEmpagliflozin | 66 | $76,409 |
| BrilintaTicagrelor | 37 | $30,122 |
| Praluent PenAlirocumab | 28 | $18,980 |
| VerquvoVericiguat | 21 | $15,466 |
| FarxigaDapagliflozin Propanediol | 14 | $15,259 |
| Ranolazine ErRanolazine | 62 | $14,152 |
| Metoprolol Succinate | 783 | $10,124 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 310 | $8,425 |
| Atorvastatin Calcium | 674 | $8,302 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 393 | $7,324 |
| Rosuvastatin Calcium | 472 | $6,956 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $11,641 | $1,079,2461,064 claims |
| NovartisEntresto | $274 | $177,212147 claims |
| Johnson & JohnsonXarelto | $883 | $127,302128 claims |
| Boehringer IngelheimJardiance | $1,050 | $76,40966 claims |
| AstraZenecaBrilinta, Farxiga | $257 | $45,38151 claims |
| MerckVerquvo | $347 | $15,46621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 429 cardiovascular disease providers in Tennessee.
Other cardiovascular disease in Lebanon
- Brian LindmanNashville$5.5M
- David MetzgerKingsport$4.8M
- Christopher EllisNashville$4.1M
- Dinesh GuptaNashville$3.2M
- Joann LindenfeldNashville$2.2M
- Frank McGrewMemphis$2.1M
- Rebecca HungNashville$1.8M
- Mohsin AlhaddadJackson$1.8M
- Robert SmithBrentwood$1.3M
- Travis RichardsonNashville$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.